Overview

Ofatumumab in AQP4-IgG Seropositive NMOSD

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, multicentre prospective pilot study to assess the efficacy and safety of ofatumumab in patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) in China.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Tang-Du Hospital

Collaborator:

Henan Provincial People's Hospital

Treatments:

Ofatumumab